Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: An international, multicenter study

International Clinical Psychopharmacology

Volumn 24, Issue 5, 2009, Pages 229-238

  Alptekin, Koksal ^a   Hafez, Jamal ^e   Brook, Shlomo ^f   Akkaya, Cengiz ^b   Tzebelikos, Errikos ^g   Ucok, Alp ^d   Tallawy, Hamdy El ^h   Danaci, Aysen Esen ^c   Lowe, Wing ⁱ   Karayal, Onur N ⁱ  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

^c CELAL BAYAR UNIVERSITY   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

^e Dar Al Ajaza Al Islamyah Hospital   (Lebanon)

^f Department of Psychiatry ^*

^g SISMANOGLIO HOSPITAL   (Greece)

^h Assiut University Faculty of Medicine   (Egypt)

ⁱ PFIZER INC   (United States)

Author keywords

Antipsychotics; Haloperidol; Olanzapine; Risperidone; Schizophrenia; Switch; Ziprasidone

Indexed keywords

ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LORAZEPAM; OLANZAPINE; PROPRANOLOL; RISPERIDONE; ZIPRASIDONE; ZOLPIDEM;

ADULT; AGED; AKATHISIA; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOOD; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 69549090006     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32832c2624     Document Type: Article

References (30)

1. American Psychiatric Associatuon (1987). Global Assessment of Functioning Scale (GAF) in DSM-III-R. Washington: American Psychiatric Association.
2. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
3. Bartkó G, Trixler M, Bitter I, Degrell I, Füredi J, Faludi G, et al. (2006). Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics [in Hungarian]. Neuropsychopharmacol Hung 8:201-209.
4. Davis JM, Leucht S (2008). Commentary on strategies for switching antipsychotics. BMC Med 6:18.
5. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA (2006). Effectiveness of switching antipsychotic medications. Am J Psychiatry 163:2090-2095.
6. Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ (2008). Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med 6:17.
7. Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR (2003). Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. J Am Pharm Assoc 47:373-378.
8. Guy W (1976). ECDEU assessment manual for psychopharmacology. US Department of Health Education and Welfare Publication (ADM) 76-338. Rockville, Maryland: National Institute for Mental Health.
9. Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, et al. (2004). Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 66:101-113. (Pubitemid 38041108)
10. Hogan TP, Awad AG, Eastwood R (1983). A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13:177-183.
11. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276. (Pubitemid 18039085)
12. Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA (2006). Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 31:577-588.
13. Lublin H, Haug H-J, Koponen H, Sigmundsson T, Kolb S (2008). Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: A 12-week open-label, multicentre clinical trial. World J Biol Psychiatry Sep 19:1-9 [Epub ahead of print].
14. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G (2004). A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161:818-825. (Pubitemid 38625334)
15. Montes JM, Rodriguez JL, Balbo E, Sopelana P, Martin E, Soto JA, et al. (2007). Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry 31:383-388. (Pubitemid 46209421)
16. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
17. Overall JE, Gorham DR (1962). The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
18. Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B (2005). The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 76:267-272.
19. Rossi A, Vita A, Tiradritti P, Romeo F (2008). Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol 23:216-222.
20. Scheifler PL, Weiden PJ (2006). Beyond psychopharmacology. Psychosocial strategies for getting the best results when switching antipsychotic medications. Postgrad Med Sep; Spec No. 45-53.
21. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611-622. (Pubitemid 44464570)
22. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
23. Weiden PJ (2006). Switching in the era of atypical antipsychotics. An updated review. Postgrad Med Sep; Spec No. 27-44.
24. Weiden PJ (2007a). Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry 68 (Suppl 1):12-19. (Pubitemid 46256966)
25. Weiden PJ (2007b). Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatr 68 (Suppl 4):34-39. (Pubitemid 46762121)
26. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL (2003a). Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 64:580-588.
27. Weiden PJ, Daniel DG, Simpson G, Romano SJ (2003b). Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 23:595-600. (Pubitemid 37443191)
28. Weiden PJ, Young AH, Buckley PF (2006). The art and science of switching of antipsychotic medications, part 1. J Clin Psychiatry 67:e15.
29. Weiden PJ, Miller AL, Lambert TJ, Buckley PF (2007). The art and science of switching antipsychotic medications, part 2. J Clin Psychiatry 68:e02.
30. Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE (2008). Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 33:985-994.